HU Group. has filed a patent for a measurement method that involves using sandwich immunoassay to measure a fragment containing a human type IV collagen 7S domain in a sample. The method utilizes a capture antibody and a labeled antibody, both of which are capable of binding specifically to the human type IV collagen 7S domain. The capture antibody is immobilized on a carrier, while the labeled antibody binds to a labeling substance. GlobalData’s report on HU Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on HU Group, was a key innovation area identified from patents. HU Group's grant share as of September 2023 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Measurement method for detecting human type iv collagen 7s domain
A recently filed patent (Publication Number: US20230296594A1) describes a measurement method for detecting a fragment containing a human type IV collagen 7S domain in a sample. The method utilizes a sandwich immunoassay technique, where a capture antibody and a labeled antibody are used to specifically bind to the human type IV collagen 7S domain.
The measurement method involves two steps. First, the sample is contacted with the capture antibody to capture the fragment containing the human type IV collagen 7S domain. Then, after the capturing step, the labeled antibody is contacted with the captured fragment to label it. This allows for the detection and measurement of the fragment in the sample.
One important aspect of the measurement method is the salt concentration of the reaction system. The patent claims that a salt concentration of 0.35 M or more is required for optimal results. This suggests that the salt concentration plays a crucial role in the accuracy and sensitivity of the measurement method.
The patent also describes a kit that can be used for implementing the measurement method. The kit includes a first monoclonal antibody that specifically binds to the human type IV collagen 7S domain, as well as a carrier that can bind to the first monoclonal antibody. Additionally, the kit includes a second monoclonal antibody that specifically binds to the human type IV collagen 7S domain, along with a labeling substance that can bind to the second monoclonal antibody. The kit provides the necessary components for conducting the sandwich immunoassay and measuring the fragment in a sample.
In summary, the filed patent describes a measurement method and a corresponding kit for detecting a fragment containing a human type IV collagen 7S domain in a sample. The method utilizes a sandwich immunoassay technique and involves capturing the fragment with a capture antibody and labeling it with a labeled antibody. The patent also emphasizes the importance of a specific salt concentration in the reaction system for optimal results. The kit includes the necessary antibodies and labeling substances for implementing the measurement method.
To know more about GlobalData’s detailed insights on HU Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
